BioCryst sees FY25 ORLADEYO revenue $580M-$600M

The company is increasing its outlook for full year 2025 global net ORLADEYO revenue to be between $580 million and $600 million, previously $535 million to $550 million. The company now expects full year 2025 operating expenses will be $440 million to $450 million, previously $425 million to $435 million. This operating expense outlook does not reflect non-cash stock compensation expense. The company is accelerating its expectation for sustainable profitability and positive cash flows by a year. The company now expects to deliver net income and positive cash flows for full year 2025. Positive cash flow refers to the improvement in cash, cash equivalents, restricted cash and investments from year end 2024 to year end 2025, not including the impact of the $75 million Pharmakon prepayment made in April 2025.